Renoprotection of Aliskiren and Aliskiren-Pentoxifylline Combination

As the prevalence of diabetes mellitus is on the rise worldwide, the incidence of diabetic nephropathy (DN) increases. Unfortunately, the untreated DN is the most common cause of renal failure requiring renal replacement therapy. So, this book evaluate the renoprotective effect of aliskiren monotherapy and aliskiren-pentoxifylline combination, and to compare it with other renin-angiotensin system inhibitors as ACEIs and ARBs in hypertensive-diabetic type 2 patients with DN to reduce the development of DN into end stage renal disease.

Autorentext

Mohammed M. Taha, Master degree in Pharmacology from Faculty of Pharmacy at Al-Azhar University-Gaza. Lecturer at Department of Pharmacology and Medical Sciences, Faculty of Pharmacy at Al-Azhar University-Gaza.